Indaptus Therapeutics (INDP) Interest & Investment Income (2022 - 2023)
Indaptus Therapeutics (INDP) posted quarterly Interest & Investment Income of $6412.0 for Q3 2023, down 87.15% year-over-year from $49904.0 in Q3 2022, and down 94.56% quarter-over-quarter from $117895.0 in Q2 2023.
Indaptus Therapeutics (INDP) Interest & Investment Income (2022 - 2023) Analysis & Trends
Indaptus Therapeutics' Interest & Investment Income history runs 2 years deep, the most recent figure standing at $6412.0 for Q3 2023.
- In Q3 2023, Interest & Investment Income fell 87.15% year-over-year to $6412.0; the TTM figure through Dec 2023 stood at $334559.0 (up 62.06% YoY), while the FY2023 annual figure was $334559.0, up 62.06% from the prior year.
- Interest & Investment Income for Q3 2023 stood at $6412.0, down from $117895.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $210252.0 in Q1 2023, with the low at -$17716.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 6,412.00 |
| Jun 30, 2023 | 117,895.00 |
| Mar 31, 2023 | 210,252.00 |
| Dec 31, 2022 | 183,469.00 |
| Sep 30, 2022 | 49,904.00 |
| Jun 30, 2022 | -17,716.00 |
| Mar 31, 2022 | -9,221.00 |